within Pharmacolibrary.Drugs.V_Various.V04C_OtherDiagnosticAgents.V04CD01_Metyrapone;

model Metyrapone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 2.5e-05,
    adminDuration = 600,
    adminMass = 750 / 1000000,
    adminCount = 1,
    Vd = 0.0011,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0016666666666666668,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Metyrapone</td></tr><tr><td>ATC code:</td><td>V04CD01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>750</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1500</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Metyrapone is an inhibitor of adrenal steroidogenesis by blocking 11-β-hydroxylase, leading to decreased cortisol synthesis. It is primarily used as a diagnostic agent for hypothalamic-pituitary-adrenal (HPA) axis disorders and, less commonly, as a treatment for Cushing's syndrome. It has been used clinically for many years and remains available as a diagnostic drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults following oral administration; no comprehensive human population PK models published in indexed literature.</p><h4>References</h4><ol><li><p>Spitz, IM, et al., &amp; Wade, CE (1993). The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics. <i>Acta endocrinologica</i> 128(5) 459–465. DOI:<a href=\"https://doi.org/10.1530/acta.0.1280459\">10.1530/acta.0.1280459</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8391196/\">https://pubmed.ncbi.nlm.nih.gov/8391196</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V04CD01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Metyrapone;
